immunotherapy

Adding a check point inhibitor to chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) produced significant improvements of pathological complete response (pCR) in comparison to chemotherapy alone. The CheckMate-816 study, presented at the American Association for Cancer…

There was a time when all that oncologists treating solid tumours needed to know about leukocytes was how to measure the damage that cytotoxic drugs inflicted on their patients’ white blood cell count and their capacity to fight off infections.…

Adverse effects of cancer therapies have long been at the root of decision making for interventions in all modalities – surgery, radiotherapy and medical – and especially in the latter category of anti-cancer drugs. Most people have heard of some…

Cancer patients receiving immunotherapy drugs have a much higher incidence of cardiac events than previous estimates from pharmacovigilance data, reports a nationwide Danish registry. The study, published in the European Heart Journal, found patients with lung cancer or malignant melanoma…

A review of trials of immunotherapy agents revealed a ‘considerable gap’ in the use of patient reported outcomes (PROs), reports a recent study. The data analysis study found PROs were included in less than half of the 44 immunotherapy trials…